After Alkermes (ALKS) announced detailed results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1, Leerink said the full data was “solid” and “about as expected.” The cataplexy data also had a significant degree of variability, which impacted the results, but the firm thinks this can probably be addressed in the Phase 3 study. “Importantly,” there were no new safety signals in the open label extension in patients who titrated up from 6 mg to 8 mg, which the firm calls “positive” and suggestive of improved safety with patients getting used to the orexin. The firm maintains a Market Perform rating on Alkermes shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Promising Clinical Results and Market Potential Drive Buy Rating for Alkermes
- Alkermes narcolepsy type 1 data largely as expected, says Mizuho
- Alkermes Announces Positive Phase 2 Study Results
- Alkermes announces Vibrance-1 study meets primary endpoint
- Alkermes initiated with an Overweight at Wells Fargo